

Annex H: Indicative non-binding estimated quantities FLD

Estimated quantities in basic units (tablets, kits) for the period 1st January 2021 to 31 December 2021	
FLDs *	Total estimates, rounded (in basic units)
Schedule n°1	
4-FDC/RHZE 150/75/400/275 (blister)	400 000 000
3-FDC/RHE 150/75/275 (blister)	35 000 000
2-FDC/RH 150/75 (blister)	800 000 000
2-FDC/3HP 300/300 (blister)	10 000 000
3-FDC/RHZ 75/50/150 (blister)	35 000 000
2-FDC/RH 75/50 (blister)	95 000 000
Schedule n°2	
Ethambutol 400mg (blister)	20 000 000
Isoniazid 300mg (blister)	250 000 000
Pyrazinamide 400mg (blister)	10 000 000
Pyrazinamide 500mg (blister)	12 000 000
Rifampicin 150mg (blister)	10 000 000
Rifampicin 300mg (blister)	5 000 000
Rifabutin 150mg (blister/container)	100 000
Rifapentine 150 mg (blister)	2 500 000
Isoniazid 100mg (blister)	1 000 000
Isoniazid 100mg (blister) dispersible tablets	45 000 000
Ethambutol 100mg (blister)	10 000 000
Ethambutol 100mg (blister) dispersible tablets	20 000 000
Pyrazinamide 150mg (blister/container) dispersible tablets	500 000
Schedule n°3	
StopTB patient kit: Cat I & III type A	700 000
Schedule n°4	
Pyridoxine 50 mg (blister)	100 000 000
Pyridoxine 100 mg (blister/container)	20 000 000

Remarks:

**-For detailed product specifications please refer to the Annex B of the ITB document*